Lessons from Iraq: preserving safe pharmaceutical distribution in periods of unrest and upheaval

3 April 2020

As companies consider the prospect of long-term disruption caused by the coronavirus, Ali Mosawi, chairman of leading Iraqi pharmaceutical agent Al Hayat, provides an Expert View from 25 years of working in one of the world’s most misunderstood markets.

Al Hayat, now one of Iraq’s oldest pharmaceutical agents, was founded in 1994 in the aftermath of the first Gulf war. My vision for the company grew from seeing first-hand the chronic shortage of life-saving medicines caused by Saddam Hussein’s refusal to implement the United Nations’ Oil for Food Resolution.

'Our core purpose has remained the same'

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK